Fig. 8
A cell-based assay shows the inhibition of IL-1α downstream signaling by SL1067 in a dose-dependent manner. Shown are the global fits (mean ± S.D., n = 3) to a four-parameter sigmoidal dose response model of the modified aptamer concentration vs. the cytokine secretion normalized to the percent of control (no modified aptamer condition). a, b SL1067 inhibits the secretion of IL-6, a downstream effector of IL-1 receptor signaling42 in HS27 (open circles) and HuVEC (open diamonds). The mean (±S.D.) half minimal inhibitory concentration (IC50) from three replicates are 22 ± 1.8 nM and 2.7 ± 0.73 nM in HS27 and HuVEC cells, respectively. c, d SL1067 inhibits the secretion of IL-8, another downstream effector of IL-1 receptor pathway42 in HS27 (open circles) and HuVEC (open diamonds). The IC50 (±S.D.) from three replicates are 23 ± 3.6 nM and 3.5 ± 0.70 nM in HS27 and HuVEC cells, respectively
